Shanghai, China, March 11, 2024 – Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical leader in the discovery, development, and commercialization of innovative drugs for genitourinary tumors and related diseases announced that it will present two latest preclinical research findings in poster format at the American Association for Cancer Research (AACR) Annual Meeting, scheduled to take place from April 5th to 10th, 2024, in San Diego, United States. The details of the poster presentations are as follows:
*APL-1202 enhances anti-tumor immune response through induction of cellular stress signaling and immunogenic cell death pathway in cancer cells
Poster number：5272
Section：2
Poster Board Number：14
Session Date and Time: April 9, 2024, 1:30 PM – 5:00 PM
*ASN-3186 is a potent and selective inhibitor of USP1 for the treatment of BRCA1/2 mut and HRD+ cancers
Poster number：7147
Poster Board Number：9
Section：23
Session Date and Time: April 10, 2024, 9:00 AM – 12:30 PM
The AACR Annual Meeting is one of the oldest and largest academic conferences focused on cancer research globally. The conference highlights high-quality research and innovation in various aspects of oncology, making it a focal point for global cancer research. It gathers the most cutting-edge research findings in the field of oncology. The abstract contents have been published on the official website of AACR.
*ASN-3186, also known as AT-012.
About Asieris
Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. We strive to improve human health to preserve patient’s dignity. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus, as we provide best-in-class integrated diagnosis and treatment solutions for patients in China and worldwide.
The company has been developing its proprietary R&D platform and core technologies, exploring new mechanisms of action, and efficiently screening and evaluating drug candidates. With a well-established in-house R&D system and expertise in global drug development, Asieris is committed to launching first-in-class drugs and other innovative products to address huge unmet needs in its areas of focus.
Asieris is also enhancing its pipeline for genitourinary diseases via proprietary R&D and strategic partnerships, while closely following cutting-edge technologies and therapeutics. The company strives to discover and identify unmet clinical needs, and adopts a forward-looking approach in product planning and life-cycle management. We aim to establish an outstanding portfolio that covers diagnosis and treatment in a bid to benefit more patients in China and globally.
